Factors contributing to increased platelet reactivity in people with diabetes

Diabetes Care

Volumn 32, Issue 4, 2009, Pages 525-527

  Schneider, David J ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIOGLITAZONE;

APOPTOSIS; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; INFLAMMATION; INSULIN DEFICIENCY; INSULIN RESISTANCE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; REVIEW; SYSTEMIC DISEASE; THROMBOCYTE FUNCTION;

BLOOD PLATELETS; DIABETES COMPLICATIONS; DIABETES MELLITUS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; OXIDATIVE STRESS; PLATELET MEMBRANE GLYCOPROTEINS;

EID: 65349117529     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc08-1865     Document Type: Review

References (25)

1. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Sabaté M, Jimenez-Quevedo P, Hernández R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Costa MA, Bass TA, Macaya C: Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 54:2430-2435, 2005
2. Vaidyula VR, Boden G, Rao AK: Platelet and monocyte activation by hyperglyce-mia and hyperinsulinemia in healthy subjects. Platelets 17:577-585, 2006
3. Yngen M, Norhammar A, Hjemdahl P, Wallén NH: Effects of improved metabolic control on platelet reactivity in patients with type 2 diabetes mellitus following coronary angioplasty. Diab Vasc Dis Res 3:52-56, 2006
4. Winocour PD, Watala C, Kinlough-Rath-bone RL: Membrane fluidity is related to the extent of glycation of proteins, but not to alterations in the cholesterol to phos-pholipid molar ratio in isolated platelet membranes from diabetic and control subjects. Thromb Haemost 67:567-571, 1992
5. Keating FK, Sobel BE, Schneider DJ: Effects of increased concentrations of glucose on platelet reactivity in healthy subjects and in patients with and without diabetes. Am J Cardiol 92:1362-1365, 2003
6. Assert R, Scherk G, Bumbure A, Pirags V, Schatz H, Pfeiffer AF: Regulation of protein kinase C by short term hyperglycae-mia in human platelets in vivo and in vitro. Diabetologia 44:188-195, 2001
7. Tschoepe D, Roesen P, Kaufmann L, Schauseil S, Kehrel B, OstermannH, Gries FA: Evidence for abnormal platelet glyco-protein expression in diabetes mellitus. Eur] Clin Invest 20:166-170, 1990
8. Pedreño J, Hurt-Camejo E, Wiklund O, Badimón L, Masana L: Platelet function in patients with familial hypertriglyceride-mia: evidence that platelet reactivity is modulated by apolipoprotein E content of very-low-density lipoprotein particles. Metabolism 49:942-949, 2000
9. Westerbacka J, Yki-Järvinen H, Tur-peinen A, Rissanen A, Vehkavaara S, Syr-jälä M, Lassila R: Inhibition of platelet-collagen interaction: an in vivo action of insulin abolished by insulin resistance in obesity. Arterioscler Thromb Vasc Biol 22: 167-172, 2002
10. i. J Biol Chem 279:3254-3264, 2004
11. Basili S, Pacini G, Guagnano MT, Mani-grasso MR, Santilli F, Pettinella C, Ciabat-toni G, Patrono C, Davì G: Insulin resistance as a determinant of platelet activation in obese women. J Am Coll Cardiol 48:2531-2538, 2006
12. Murakami T, Horigome H, Tanaka K, Na-kata Y, Ohkawara K, Katayama Y, Matsui A: Impact of weight reduction on production of platelet-derived microparticles and fibrinolytic parameters in obesity. Thromb Res 119:45-53, 2007
13. Hoehn KL, Hohnen-Behrens C, Ceder-berg A, Wu LE, Turner N, Yuasa T, Ebina Y, James DE: IRS1-independent defects define major nodes of insulin resistance. Cell Metab 7:421-433, 2008
14. Betteridge D, El Tahir K, Reckless J, Williams K: Platelets from diabetic subjects show diminished sensitivity to prostacyclin. Eur J Clin Invest 12:395-398, 1982
15. Anfossi G, Mularoni EM, Burzacca S, Pon-ziani MC, Massucco P, Mattiello L, Cav-alot F, Trovati M: Platelet resistance to nitrates in obesity and obese NIDDM, and normal platelet sensitivity to both insulin and nitrates in lean NIDDM. Diabetes Care 21:121-126, 1998
16. Handin RI, Karabin R, Boxer GJ: Enhancement of platelet function by super-oxide anion. J Clin Invest 59:959-965, 1977
17. + signalling in diabetic patients is due to increased formation of superoxide anions and reduced nitric oxide production. Diabetologia 42:167-176, 1999
18. Freedman JE: Oxidative stress and platelets. ArteriosclerThromb VascBiol 28:S11-S16, 2008
19. Spinetti G, Kraenkel N, Emanueli C, Mad-eddu P: Diabetes and vessel wall remodelling: from mechanistic insights to regenerative therapies. Cardiovasc Res 78: 265-273, 2008
20. Schäfer A, Bauersachs J: Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activationindiabe-tes and atherosclerosis. Curr Vasc Pharmacol 6:52-60, 2008
21. Lim HS, Blann AD, Lip GY: Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation 109: 2524-2528, 2004
22. Stratmann B, Tschoepe D: Pathobiology and cell interactions of platelets in diabetes. Diab Vasc Dis Res 2:16-23, 2005
23. Keating FK, Schneider DJ: The influence of platelet activating factor on the effects of platelet agonists and antiplatelet agents in vitro. J Thromb Thrombolysis. 25 June 2008 [Epub ahead of print]
24. Calverley DC, Hacker MR, Loda KA, Brass E, Buchanan TA, Tsao-Wei DD, Groshen S: Increased platelet Fc receptor expression as a potential contributing cause of platelet hypersensitivity to collagen in diabetes mellitus. Br J Haematol 121:139-142, 2003
25. Belostocki K, Pricop L, Redecha PB, Aydin A, Leff L, Harrison MJ, Salmon JE: Inflix-imab treatment shifts the balance between stimulatory and inhibitory Fcgamma receptor type II isoforms on neutrophils in patients with rheumatoid arthritis. Arthritis Rheum 58:384-388, 2008